Matthew Rabinowitz, Executive Chairman of Natera, Inc. (NASDAQ:NTRA), sold 100,000 shares of common stock for approximately $21.4 million through multiple transactions on June 12 and June 15, 2026. The shares were sold at weighted average prices ranging from $209.4953 to $219.3581.
These sales were conducted pursuant to a Rule 10b5-1 trading plan, which Mr. Rabinowitz adopted on March 13, 2026. On June 12, Mr. Rabinowitz disposed of 50,000 shares. These transactions occurred at prices ranging from $208.88 to $219.98 per share. On June 15, an additional 50,000 shares were sold, with prices ranging from $209.27 to $218.84 per share.
Following these transactions, Mr. Rabinowitz directly holds 2,277,843 shares of Natera common stock. An additional 5,000 shares are held indirectly by his spouse. The insider sale comes as Natera’s stock has delivered a 31% return over the past year, currently trading at $220.11 with a market capitalization of $31.4 billion. According to InvestingPro analysis, the stock appears overvalued relative to its Fair Value. Investors seeking deeper insights can access comprehensive analysis through Natera’s Pro Research Report, available for this and 1,400+ other US equities.
In other recent news, Natera Inc. announced that its shareholders have approved an amendment to the company’s 2015 Equity Incentive Plan, increasing the number of shares reserved for issuance by 3.2 million. This decision was made during the company’s annual meeting, where directors were also elected. Additionally, Natera has expanded its board of directors by appointing two oncology experts, Thomas Lynch and Eric Rubin, adding significant experience to its leadership team. Natera IncFollowAnalyze NTRAIncluded in our AI-picked strategies·Review strategies220.11▲+3.14(+1.45%)Closed·15:59:59·USD220.10▼-0.01(-0.00%)After Hours·21:08:151D1W1M6M1Y5YMaxCreated with Highcharts 11.4.814:0015:0016:0017:0018:0019:00210215220Analyze NTRARBC Capital has initiated coverage of Natera with an Outperform rating, highlighting growth opportunities in minimal residual disease monitoring. Wolfe Research also initiated coverage with an Outperform rating, setting a price target of $260 based on a long-term growth model. Meanwhile, Goldman Sachs has given Natera a Neutral rating, with a price target of $245, acknowledging the company’s leadership in the minimal residual disease market. These recent developments reflect a focus on expanding leadership and exploring growth opportunities in the healthcare sector. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.Is NTRA a bargain right now?The fastest way to find out is with our Fair Value calculator. We use a mix of 17 proven industry valuation models for maximum accuracy.Get the bottom line for NTRA plus thousands of other stocks and find your next hidden gem with massive upside.Flash Sale - Price Goes Up Soon